High doses of vitamin D may stop colorectal cancer from spreading for over one year
Extra vitamin D may slow the growth of colorectal cancer, a new study suggests.
On average, cancer stopped in its tracks for 13 months for patients on the highest dose of the vitamin supplement (4,000 IU), and for 11 months for those on the over-the-counter dose.
Rates of colorectal cancer have been soaring in recent years, especially among young people who are often misdiagnosed until their disease is already in its late stages.
But the new study, from the Dana-Farber Cancer Institute, suggests that high doses of vitamin D might keep the devastating disease at bay – even in its late stages.
Study co-author and director of research for Dana-Farber’s Gastrointestinal Cancer Center, Dr. Kimmie Ng, called the findings “very important.”
“It identifies a cost-effective, safe, and easily accessible agent as a potential new treatment for metastatic colorectal cancer.”
That is particularly key because studies suggest that as many as 71 percent of under-50s diagnosed with colorectal cancer are already in the third or fourth stage of the disease, when it has spread into nearby tissues or metastasized to further organs.
At these stages, the cancer becomes much more deadly.
While colorectal cancer is isolated its original organs, the five-year survival rate is 90 percent. Once it expands to surrounding areas, like the lymph nodes, that rate drops to 71 percent.
But once it metastasizes, the five-year survival rate plummets to 14 percent. Targeted therapies and immunotherapies are available to treat colorectal cancer, but only some forms. For the rest, the standard treatment is chemotherapy.
But the new study, published in JAMA, suggests that adding vitamin D to a treatment regimen could temporarily freeze the disease progression and potentially extend life expectancy.
It isn’t clear why, but those with higher blood levels of vitamin D have lower risks of colorectal cancer to begin with.
And the vitamin seems to activate the suicide switch in cells that can kill them when they become cancerous, according to previous lab studies.
So the Dana Farber Institute researchers enrolled a small number of metastatic colorectal cancer patients – 139 – who had not yet had any treatment.
All of the patients were started on chemo and a targeted therapy called bevacizumab (sold as Avastin). Half of the patients were put on a regimen of one 400 IU vitamin D capsule a day.
The other half took two 4,000 IU capsules a day for two weeks, then switched to one 4,000 IU capsule a day for the remainder of the study (on average, patients remained on the regimen for just short of 23 months).
Both groups saw significant delays in the progress of the disease.
Though it’s hard to say if or how quickly the cancer would have continued to spread on just chemo and targeted therapy, the cancer didn’t budge for an average of 13 months for the high-dose group or for 11 months for the low-dose group.
Over the course of the nearly two years of the study, cancer was 36 percent less likely to keep spreading or prove fatal in patients on high doses of vitamin D than it was in those who took the lower dose.
Vitamin D is looking very promising, but to the authors’ knowledge, this is the first time its benefits for colorectal cancer have been studied – and it’s still early days.
“The results of our trial suggest an improved outcome for patients who received vitamin D supplementation, and we look forward to launching a larger trial to confirm these exciting and provocative findings,” said senior study author Dr. Charles Fuchs, a former Dana-Farber oncologist who is now at Yale University.